Chemomab Therapeutics

CMMB · NASDAQ

$1.18+$0.01 (+0.85%)TodayMarket closed · Oct 20, 7:40 PM ET

Prev close $1.17

About CMMB

Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company employs 12 full-time employees The company went IPO on 2012-08-14. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees: 12
Headquarters: TEL AVIV-YAFO
Listed: Aug 14, 2012
Sector: Health Care
Industry: Biotechnology
Website: chemomab.com

Leadership

Chemomab Therapeutics executives
Name	Title	Since	Age
Nissim Darvish	—	—	57
Adi Mor	—	2021	41
Sigal Fattal	—	—	51
Jack Lawler	—	—	—
David Weiner	—	—	—
Neil Cohen	—	—	58
Alan Moses	—	—	77
Claude Nicaise	—	—	69
Irina Koffler	—	2020	—

Similar companies

Companies in the same industry as Chemomab Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.